Kadmon Corp LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kadmon Corp LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013479
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kadmon Corp LLC (Kadmon) is a biopharmaceutical company that offers products and related services for the management and treatment of hepatitis C. The company also develops therapies for metabolic and serious diseases. Its products include ribavirin, USP Tablets, ribavirin capsules, phentermine and topiramate extended-release capsules and trientine hydrochloride. Kadmon offers products in the therapeutic areas of oncology, infectious diseases, immunology, and neurodegenerative disease. The company’s discovery platforms include metabolomics, chromics, monoclonal antibodies, synthetic biology and gene regulation. It undertakes identification and evaluation of investigational compounds, which show the potential to improve patient outcomes. Kadmon is headquartered in New York, the US.

Kadmon Corp LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kadmon Acquires Rights To Salirasib From Concordia Pharma 12
Venture Financing 13
Kadmon Raises USD5.7 Million in Venture Financing 13
Kadmon Raises US$4.7 Million In Venture Financing 14
Kadmon Pharma Secures US$40 Million In Venture Financing 15
Partnerships 16
Kadmon Amends Distribution Agreement with Camber Pharma 16
Kadmon Enters into R&D Agreement with NIDCR 17
EffRx Pharma Enters An Agreement With Kadmon 18
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 19
Kadmon Pharma Forms Joint Venture With Nano Terra 20
Licensing Agreements 22
Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 22
Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 23
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 24
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 25
Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 27
Dyax Enters Into Licensing Agreement With Kadmon 28
Equity Offering 29
Kadmon Plans to Raise USD40 Million in Public Offering of Shares 29
Kadmon Plans to Raise Funds through Public Offering of Shares 30
Kadmon Prices IPO for USD75 Million 31
Kadmon Raises USD11 Million in Private Placement of Units 33
Kadmon Raises USD5.5 Million in Private Placement of Units 34
Kadmon Raises USD10 Million in Private Placement of Units 35
Kadmon Raises USD35 Million in Private Placement of Units 36
Kadmon Raises USD15 Million in Private Placement of Units 37
Asset Transactions 38
AbbVie Acquires Rights to Ribasphere from Kadmon 38
Acquisition 39
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 39
Kadmon Corp LLC – Key Competitors 40
Kadmon Corp LLC – Key Employees 41
Kadmon Corp LLC – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Sep 07, 2016: Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016 43
Clinical Trials 44
Apr 14, 2016: Kadmon to Present Preclinical Data Demonstrating that its Novel Immuno-Oncology Compound Achieves Long-Lasting and Persistent Antitumor Immunity 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Key Facts 2
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kadmon Corp LLC, Deals By Therapy Area, 2011 to YTD 2017 9
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kadmon Acquires Rights To Salirasib From Concordia Pharma 12
Kadmon Raises USD5.7 Million in Venture Financing 13
Kadmon Raises US$4.7 Million In Venture Financing 14
Kadmon Pharma Secures US$40 Million In Venture Financing 15
Kadmon Amends Distribution Agreement with Camber Pharma 16
Kadmon Enters into R&D Agreement with NIDCR 17
EffRx Pharma Enters An Agreement With Kadmon 18
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 19
Kadmon Pharma Forms Joint Venture With Nano Terra 20
Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 22
Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 23
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 24
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 25
Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 27
Dyax Enters Into Licensing Agreement With Kadmon 28
Kadmon Plans to Raise USD40 Million in Public Offering of Shares 29
Kadmon Plans to Raise Funds through Public Offering of Shares 30
Kadmon Prices IPO for USD75 Million 31
Kadmon Raises USD11 Million in Private Placement of Units 33
Kadmon Raises USD5.5 Million in Private Placement of Units 34
Kadmon Raises USD10 Million in Private Placement of Units 35
Kadmon Raises USD35 Million in Private Placement of Units 36
Kadmon Raises USD15 Million in Private Placement of Units 37
AbbVie Acquires Rights to Ribasphere from Kadmon 38
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 39
Kadmon Corp LLC, Key Competitors 40
Kadmon Corp LLC, Key Employees 41
Kadmon Corp LLC, Other Locations 42
Kadmon Corp LLC, Subsidiaries 42

★海外企業調査レポート[Kadmon Corp LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Stanwell Corporation Ltd:発電所・企業SWOT分析
    Stanwell Corporation Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Clearside BioMedical Inc (CLSD):医療機器:M&Aディール及び事業提携情報
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • CRH public limited company (CRG):企業の財務・戦略的SWOT分析
    CRH public limited company (CRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • First Abu Dhabi Bank PJSC (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank PJSC (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Respiri Ltd (RSH):医療機器:M&Aディール及び事業提携情報
    Summary Respiri Ltd (Respiri), formerly iSonea Ltd, is a medical technology company that develops non-invasive medical devices and mobile health applications to improve the management of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The company’s prop …
  • Protokinetix Inc (PKTX):企業の財務・戦略的SWOT分析
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務情報
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Nymox Pharmaceutical Corp (NYMX)-医療機器分野:企業M&A・提携分析
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Shinhan Bank:企業の戦略・SWOT・財務分析
    Shinhan Bank - Strategy, SWOT and Corporate Finance Report Summary Shinhan Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Seven Seas Cruises S. DE R.L.:企業の戦略・SWOT・財務情報
    Seven Seas Cruises S. DE R.L. - Strategy, SWOT and Corporate Finance Report Summary Seven Seas Cruises S. DE R.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Wentworth Resources Ltd (WRL)-石油・ガス分野:企業M&A・提携分析
    Summary Wentworth Resources Limited (Wentworth) is an independent upstream oil and gas company. It conducts the exploration and development of oil and natural gas reserves. The company has producing gas assets in Tanzania, oil and gas exploration activities in both Mozambique and Tanzania. The compa …
  • Societe Nationale d’Operations Petrolieres de la Cote d’Ivoire:石油・ガス:M&Aディール及び事業提携情報
    Summary Societe Nationale d'Operations Petrolieres de la Cote d'Ivoire (Petroci) is an oil and gas company that explores, produces and trades petroleum products and by-products. The company offers butane gas, natural gas and LPG. It provides oil trading and logistics services. Petroci conducts geolo …
  • Chiome Bioscience Inc (4583):製薬・医療:M&Aディール及び事業提携情報
    Summary Chiome Bioscience Inc (Chiome Bioscience) is a healthcare service company that provides research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating syst …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務分析
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Adimmune Corp (4142):製薬・医療:M&Aディール及び事業提携情報
    Summary Adimmune Corp (Adimmune) is a biopharmaceutical company that manufactures diagnostics, vaccines, and biological products for various diseases. The corporation’s products include tetanus toxoid adsorbed vaccine, influenza vaccine, Japan encephalitis vaccine, and ah1n1 vaccine. It also provide …
  • Delta Air Lines, Inc.:企業のM&A・事業提携・投資動向
    Delta Air Lines, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delta Air Lines, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Crossject SA (ALCJ):企業の財務・戦略的SWOT分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company’s pipeline products include sumatriptan for the treatment of migraines and cluster headaches; adrenaline for the treatment of anaphylactic shock; hydrocortisone for the treatment of acute adrena …
  • Prestige Brands Holdings Inc (PBH):製薬・医療:M&Aディール及び事業提携情報
    Summary Prestige Brands Holdings Inc (Prestige) focuses on the marketing, sales and distribution of over-the-counter (OTC) healthcare and household cleaning brands. The company offers its products for digestive care; lice treatment, household cleaning; hygiene; oral care; pain relief; pediatric care …
  • MaaT Pharma-製薬・医療分野:企業M&A・提携分析
    Summary MaaT Pharma (MaaT) is a biotechchnology company that develop novel treatments for Gut Microbiota - dysbiosis related diseases. The company is working on two projects, which are in the developmental stage, namely, MaaT001, an innovative live frozen inoculum suspension and MaaT002, an innovati …
  • Paratek Pharmaceuticals Inc (PRTK):企業の財務・戦略的SWOT分析
    Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆